1
|
Onoja RI, Ihedioha JI, Shoyinka SVO, Ezema AS, Emejuo NT, Mgbeahuruike AC, Emesiani BI, Obidah W, Clinton I. Inhibitory effects of Calocybe indica macrofungi on experimental benign prostatic hyperplasia in rats. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES 2023; 26:121-127. [PMID: 36594056 PMCID: PMC9790059 DOI: 10.22038/ijbms.2022.64972.14309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 11/01/2022] [Indexed: 01/04/2023]
Abstract
Objectives This study was designed to investigate the protective effects of Calocybe indica extract on testosterone-induced benign prostatic hyperplasia in rats. Materials and Methods In this study, 60 adult Sprague Dawley rats were randomly divided into six equal groups, one group served as the normal control, five of the groups were administered subcutaneous testosterone propionate for 28 days to induce benign prostatic hyperplasia, three of the five groups were simultaneously administered three graded doses of C. indica extract while one group was administered finasteride as the standard drug and the other left as untreated BPH model group given testosterone propionate only. BPH in the prostate gland was detected through gross appearance, prostate weight, and biochemical and histopathological analyses. Results Increased prostate weight, serum prostate-specific antigen (PSA), and epithelial thickness were observed in the untreated testosterone-induced BPH model. Administration of finasteride and C. indica extract led to a reduction in prostate weight, prostatic index, serum PSA, serum levels of testosterone, and prostatic epithelial thickness, and increased luminal diameter. Conclusion Administration of C. indica extract suppressed the pathophysiological effects of benign prostatic hyperplasia in rats. Thus, C. indica mushroom is a potential pharmacological candidate for the management of BPH in man or dogs.
Collapse
Affiliation(s)
- Remigius I. Onoja
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria,Corresponding author: Remigius I. Onoja. Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka. Tel: +2347037434406;
| | - John I. Ihedioha
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria
| | - Shodeinde VO. Shoyinka
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria
| | - Arinze S. Ezema
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria
| | - Nnenna T. Emejuo
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria
| | - Anthony C. Mgbeahuruike
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria
| | - Benjamin I. Emesiani
- Institute for Drug Herbal Medicine Excipients Research and Development, Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria
| | - Wilson Obidah
- Department of Biochemistry, School of Life Sciences, Modibbo Adama University of Technology Yola, Yola, Nigeria
| | - Iyi Clinton
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, 410001, Nsukka, Nigeria
| |
Collapse
|
2
|
Onoja RI, Olumuyiwa Shoyinka SV, Omeke JN, Emejuo NT, Ugwoke SN. Protective effects of Chromolaena odorata extract on experimental benign prostatic hyperplasia in rats. VETERINARY RESEARCH FORUM : AN INTERNATIONAL QUARTERLY JOURNAL 2023; 14:59-64. [PMID: 36909686 PMCID: PMC10003600 DOI: 10.30466/vrf.2021.537224.3219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Accepted: 12/20/2021] [Indexed: 03/14/2023]
Abstract
Benign prostatic hyperplasia (BPH) is an age-related disease in dogs and man leading to prostate enlargement which impinges on the urethra causing urinary outflow obstruction. Due to the side effects of surgery and chemotherapy used for the treatment of this disease, attention is now focused on phytotherapeutics for its management. Thus, we investigated the inhibitory effect of hydro-methanol extract of Chromolaena odorata (HMECO) on testosterone propionate (TP)-induced BPH rat model. A total of forty-two 10-12 weeks old male Sprague-Dawley outbred albino rats (Rattus norvegicus) weighing 200 - 250 g were randomly divided into six equal groups of seven rats each based on body weight as follows: A) Control group given phosphate-buffered saline orally and corn oil subcutaneously (SC) once daily, B) TP at a dose of 3.00 mg kg-1 SC once daily, C) TP at a dose of 3.00 mg kg-1 SC and finasteride at a dose of 10.00 mg kg-1 orally once daily, D) TP at a dose of 3.00 mg kg-1 SC plus 200 mg kg-1 HMECO orally once daily, E) TP at a dose of 3.00 mg kg-1 SC plus 400 mg kg-1 HMECO orally once daily and F) TP at a dose of 3.00 mg kg-1 SC plus 800 mg kg-1 HMECO orally once daily for 28 days. Results showed that HMECO significantly reduced prostate weight, prostatic index; serum levels of testosterone and prostatic epithelial thickness and increased luminal diameter in BPH induced rats. Thus, the results of this study suggest that C. odorata is a potential pharmacological candidate for the management of BPH.
Collapse
Affiliation(s)
- Remigius Ibe Onoja
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
| | | | - Jacinta Ngozi Omeke
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
| | - Nnenna Tochi Emejuo
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
| | - Stella Nkemdilim Ugwoke
- Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
| |
Collapse
|
3
|
Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, Kenda M, Kočevar Glavač N, Nagy M, Protti M, Mercolini L, Horváth G, Farkas Á. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules 2021; 26:molecules26237141. [PMID: 34885733 PMCID: PMC8659259 DOI: 10.3390/molecules26237141] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Revised: 11/19/2021] [Accepted: 11/20/2021] [Indexed: 12/08/2022] Open
Abstract
Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the above-mentioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.
Collapse
Affiliation(s)
- Eszter Csikós
- Department of Pharmacognosy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.C.); (K.Á.); (N.P.); (V.L.B.); (G.H.)
| | - Adrienn Horváth
- Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary;
| | - Kamilla Ács
- Department of Pharmacognosy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.C.); (K.Á.); (N.P.); (V.L.B.); (G.H.)
| | - Nóra Papp
- Department of Pharmacognosy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.C.); (K.Á.); (N.P.); (V.L.B.); (G.H.)
| | - Viktória Lilla Balázs
- Department of Pharmacognosy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.C.); (K.Á.); (N.P.); (V.L.B.); (G.H.)
| | - Marija Sollner Dolenc
- University of Ljubljana, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, SI-1000 Ljubljana, Slovenia; (M.S.D.); (M.K.)
| | - Maša Kenda
- University of Ljubljana, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, SI-1000 Ljubljana, Slovenia; (M.S.D.); (M.K.)
| | - Nina Kočevar Glavač
- University of Ljubljana, Department of Pharmaceutical Biology, Faculty of Pharmacy, SI-1000 Ljubljana, Slovenia;
| | - Milan Nagy
- Department of Pharmacognosy and Botany, Faculty of Pharmacy, Comenius University in Bratislava, SK-832-32 Bratislava, Slovakia;
| | - Michele Protti
- Research Group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (M.P.); (L.M.)
| | - Laura Mercolini
- Research Group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (M.P.); (L.M.)
| | - Györgyi Horváth
- Department of Pharmacognosy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.C.); (K.Á.); (N.P.); (V.L.B.); (G.H.)
| | - Ágnes Farkas
- Department of Pharmacognosy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.C.); (K.Á.); (N.P.); (V.L.B.); (G.H.)
- Correspondence:
| | | |
Collapse
|
4
|
Ahmed AS, Soliman MG. Protective Role of 4-(4-Hydroxy-3-methoxyphenyl)-2-Butanone on Prostatic Cells Hyperplasia of Rats and Human, 5α-reductase Inhibition Pathway. J Microsc Ultrastruct 2021; 9:164-169. [PMID: 35070691 PMCID: PMC8751679 DOI: 10.4103/jmau.jmau_37_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 05/17/2020] [Accepted: 09/03/2020] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Prostate gland is an exocrine gland that could be affected by various pathological conditions. Benign prostatic hyperplasia (BPH) is an age-dependent medical condition caused by increased activity of 5α-reductase enzyme (5α-R). Medical treatment by finasteride is considered during treatment, but it has unavoidable side effects. Hence, there is an increasing need to use natural ingredients for BPH treatment. Gingerol oil (ginger extract) is transferred by heating into zingerone. Recent studies reported the effect of zingerone on prostate cancer cells. AIMS AND OBJECTIVES The aim of the present research is to investigate the protective effect of zingerone against BPH. MATERIALS AND METHODS Sixty male Albino Wistar rats were divided into three groups: control group, prostatic hyperplasia group treated with saline, and prostatic hyperplasia group treated with zingerone (PH-Z-G). At day 28, all rats were sacrificed, epididymis and prostate samples were collected for histopathological examination and Western blotting for androgen receptors (ARs) proteins and steroid 5 alpha-reductase 1 (SRD5A1). Human RWPE-1 prostatic cell line was assessed for viability and cycle after treated with zingerone 500 μg/day for 10 days. RESULTS PH-S group showed significant (P < 0.05) thickening of connective tissue septa associated with narrowing of acinar lumen. PH-Z group showed regain of the normal histological feature. SRD5A1 and AR expression was significantly (P < 0.05) reduced in PH-Z group in comparison with PH-S group. Cell line proliferation was significantly reduced after application of zingerone with G2/M cell cycle arrest. CONCLUSION Our results showed that natural herbal zingerone decreased the prostatic tissue levels of (5α reductase and AR) in rat BPH model, which could be a promising herbal medicine for BPH treatment. Further human clinical trials are required.
Collapse
Affiliation(s)
- Ahmed S. Ahmed
- Department of Anatomy and Embryology, College of Medicine, Tanta University, Tanta, Egypt
| | | |
Collapse
|
5
|
Seo Y, Shin N, Nam HH, Song J, Cheol Moon B, Choi G, Shin I, Kim J. Effects of larval extracts from identified Protaetia brevitarsis seulensis against benign prostatic hyperplasia induced by testosterone in rats. Food Sci Nutr 2021; 9:5361-5369. [PMID: 34646508 PMCID: PMC8498080 DOI: 10.1002/fsn3.2460] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 06/03/2021] [Accepted: 06/29/2021] [Indexed: 01/15/2023] Open
Abstract
Protaetia brevitarsis seulensis is an animal-based medicine used traditionally in China, Japan, and Korea to treat hepatic disorders; it has been shown to possess various pharmacological effects such as antibacterial and antioxidant activities. In this study, we investigated the effects of P. brevitarsis on a testosterone-induced benign prostatic hyperplasia (BPH) rat model. To establish the BPH model, the animals were administered a subcutaneous injection of testosterone daily for 28 days. P. brevitarsis was administered by oral gavage at doses of 12.5, 25, and 50 mg/kg for 28 days, along with testosterone injection. P. brevitarsis treatment markedly decreased the absolute and relative prostate weight of BPH animals. The levels of dihydrotestosterone was reduced in P. brevitarsis-treated animals compared to those in the BPH animals. Histological analysis of the prostate showed that P. brevitarsis treatment effectively suppressed the testosterone-induced hyperplasia of prostatic epithelial cells, which was accompanied by reductions in the PCNA and Ki-67 expressions in prostatic tissues. These results indicate that P. brevitarsis effectively suppresses testosterone-induced development of BPH, and thus, is a potential therapeutic agent for BPH.
Collapse
Affiliation(s)
- Yun‐Soo Seo
- Herbal Medicine Resources Research CenterKorea Institute of Oriental MedicineNaju‐siKorea
| | - Na‐Rea Shin
- College of Veterinary Medicine and BK21 Plus Project TeamChonnam National UniversityGwangjuKorea
| | - Hyeon Hwa Nam
- Herbal Medicine Resources Research CenterKorea Institute of Oriental MedicineNaju‐siKorea
| | - Jun‐Ho Song
- Herbal Medicine Resources Research CenterKorea Institute of Oriental MedicineNaju‐siKorea
| | - Byeong Cheol Moon
- Herbal Medicine Resources Research CenterKorea Institute of Oriental MedicineNaju‐siKorea
| | - Goya Choi
- Herbal Medicine Resources Research CenterKorea Institute of Oriental MedicineNaju‐siKorea
| | - In‐Sik Shin
- College of Veterinary Medicine and BK21 Plus Project TeamChonnam National UniversityGwangjuKorea
| | - Joong‐Sun Kim
- Herbal Medicine Resources Research CenterKorea Institute of Oriental MedicineNaju‐siKorea
- College of Veterinary Medicine and BK21 Plus Project TeamChonnam National UniversityGwangjuKorea
| |
Collapse
|
6
|
Kim HJ, Jin BR, An HJ. Psoralea corylifolia L. extract ameliorates benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis. JOURNAL OF ETHNOPHARMACOLOGY 2021; 273:113844. [PMID: 33485982 DOI: 10.1016/j.jep.2021.113844] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 12/30/2020] [Accepted: 01/13/2021] [Indexed: 06/12/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Psoralea corylifolia L. seed (PCL), commonly known as "Poguzhi" or "BuguZhi", has been widely used to treat kidney yang deficiency in traditional Chinese medicine (TCM) where tonifying the yang deficiency is a representative understanding for treatment of hormonal deficiency disorders such as enuresis, oliguria, and prostatic diseases. Although PCL has been commonly used to treat problems of the urinary system, its efficacy against benign prostatic hyperplasia (BPH) has not yet been reported. AIM OF THE STUDY In the present study, we aimed to assess the in vitro and in vivo efficacy of PCL against BPH, a condition which negatively impacts quality of life in men. MATERIALS AND METHODS Normal human prostate cell lines, RWPE-1 and WPMY-1 cells, were stimulated with 10 nM dihydrotestosterone (DHT) to establish an in vitro BPH model. Subsequently, cells were treated with 100 or 200 μg/ml PCL, which inhibited cell proliferation without cytotoxicity, to evaluate the anti-BPH effect of PCL. Eight-week-old male Wistar rats were castrated, except for those in the control group (Con), and BPH was induced by subcutaneous injection of 10 mg/kg testosterone propionate (TP). Concurrent with daily TP injections, 5 mg/kg of finasteride (Fina) and 50 or 100 mg/kg PCL were orally administrated daily for four weeks, excluding the weekends. RESULTS In DHT-stimulated RWPE-1 and WPMY-1 cells, expression of androgen receptor (AR) androgen signaling-related markers such as 5α-reductase 2 (5AR2), AR, and prostate-specific antigen (PSA) was upregulated, whereas 100 or 200 μg/ml of PCL treatment downregulated these markers. Furthermore, PCL significantly reduced the mRNA expression of anti-apoptotic genes and increased the mRNA expression of pro-apoptotic gene. In vivo, administration of PCL reduced prostate size and weight in TP-induced BPH rats. Moreover, histological alterations in epithelium thickness were significantly restored by the administration of PCL. Immunohistochemical analysis revealed increased expression of AR and proliferating cell nuclear antigen (PCNA) in TP-induced BPH prostates; these changes were suppressed by administration of 50 or 100 mg/kg PCL. CONCLUSIONS We demonstrated the effect of PCL against BPH, mediated by the regulation of prostate cell proliferation and apoptosis, in DHT-stimulated normal human prostate cell lines and TP-induced BPH rats. These findings suggest that PCL could be a potential therapeutic agent against BPH.
Collapse
Affiliation(s)
- Hyo-Jung Kim
- Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do, 26339, Republic of Korea.
| | - Bo-Ram Jin
- Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do, 26339, Republic of Korea.
| | - Hyo-Jin An
- Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do, 26339, Republic of Korea.
| |
Collapse
|